meta_pixel
Tapesearch Logo
Log in
HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast

127 - Naloxone to the Rescue! Opioid Overdose Treatment and More

HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast

Sean P. Kane, PharmD, BCPS

Health & Fitness, Medications, Rosalindfranklin, Rfums, Pharmacy, Pharmd, Pharmacist, Medicine, Drugs

5644 Ratings

🗓️ 9 March 2021

⏱️ 44 minutes

🧾️ Download transcript

Summary

In this episode, we will discuss basic pharmacology and use of naloxone, available formulations, evidence for its effectiveness, and naloxone-related pharmacy management and regulations.

Key Concepts

  1. Naloxone, available in various formulations, is a quick-acting opioid reversal agent approved for use in opioid overdose cases.
  2. Naloxone access laws are in place in the majority of the states allowing patients and caregivers to obtain the medication as well as administer naloxone.
  3. These access laws allow pharmacists to dispense naloxone to patients without individual prescriptions under prescriptive authority, standing/protocol orders, or collaborative agreements. Registration, training, education, and reporting requirements may vary per individual state.
  4. Despite such access laws, overall prescribing of naloxone per high-dose opioid prescriptions remain low. Not many studies are available, but some suggest these laws help reduce opioid overdose deaths and emergency department visits. Implementation and education about such laws need to be improved.

References

Transcript

Click on a timestamp to play from that location

0:00.0

Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions.

0:11.0

This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy.

0:17.0

This podcast contains general information for educational purposes only. This is not

0:22.0

professional advice and should not be used in lieu of obtaining advice from a qualified

0:26.0

health care provider. And now on to the show. Welcome to Helix Talk episode 127. I'm your

0:34.7

co-host Dr. Kane. And I'm Dr. Patel. And in today's episode, we are going to

0:40.4

discuss naloxone. The title of our episode is Naloxone to the Rescue, Opioid Overdose, Treatment,

0:46.6

and more. And we're kind of hoping to cover basic pharmacology and the use of naloxone. What different

0:53.8

formulations are available in the market?

0:56.9

What's this use for effectiveness?

0:59.0

And in general, what are some of the naloxone-related pharmacy management and regulations

1:05.2

that our audience would need to know?

1:07.6

Great.

1:08.1

Well, Dr. Pertell, why don't we just start with the basic pharmacology of naloxone? So naloxone is an agent that we use to know. Great. Well, Dr. Patel, why don't we just start with the basic pharmacology of naloxone?

1:11.9

So naloxone is an agent that we use to reverse opioid overdose. So it's actually competitive

1:18.0

opioid antagonist. So in patients that overdose an opioid, this prevents that opioid from binding

1:24.1

to the opioid receptor, and it reverses the pharmacologic effect of whatever

1:28.2

they overdosed on. This is used to reverse, you know, overdose from your prescription opioids

1:34.9

or non-prescription opioids, aka street drugs like heroin. And Dr. Pertel, what would be some

1:42.8

indications in terms of signs or symptoms of an overdose

1:46.7

that may be amenable to naloxone to reverse that overdose?

1:50.5

Yeah.

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from Sean P. Kane, PharmD, BCPS, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Sean P. Kane, PharmD, BCPS and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2025.